This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and
cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic …

Background: Sacubitril/valsartan was shown to attenuate the development of cardiac
hypertrophy with enhanced blood pressure reduction compared with valsartan alone in …

Background Hypertensive left ventricular hypertrophy is associated with the risk of heart
failure, coronary heart disease and cerebrovascular disease. Although sacubitril/valsartan …

The objective was to investigate the effects of valsartan on the electrophysiological
characteristics of left ventricular hypertrophic myocardium in spontaneously hypertensive …

Objective: To test whether olmesartan ameliorates cardiac diastolic dysfunction in
spontaneously hypertensive rats (SHRs) through calcineurin pathway. Methods: Twenty-four …

Heart failure with preserved ejection fraction (HFpEF) represents a multifaceted syndrome
related to complex pathologic mechanisms. Sacubitril/valsartan (Sac/val) has demonstrated …

Background/Aims: Many clinical and experimental studies have shown that treatment with
statins could prevent myocardial hypertrophy and remodeling induced by hypertension and …

End‐stage hypertensive heart disease is an increasing cause of cardiac mortality. Therefore,
the current study focused on the cardiac remodelling from hypertrophy to fibrosis in old …

This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left
ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of …

Background Arginine vasopressin (AVP) is elevated in patients with heart failure, and the
increase in the AVP concentration in plasma is positively correlated with disease severity …